News
Stay updated on Vesigen innovations
Sign up to receive the latest company news
Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139
Vesigen Highlights Non-Human Primate Biodistribution of Non-Viral Technology and Functional Delivery of Genome Editors In Vivo at the Cracking the Code: The Dawn of Nucleic Acid Medicines Meeting
Robust uptake observed in photoreceptors and retinal pigment epithelium (RPE) of mice, minipigs, and non-human primates Additional data demonstrate rescue ...
ARMMs give a leg-up to novel biotherapeutics
By engineering naturally existing arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (known as ARMMs), Vesigen Therapeutics’ platform enables the effective delivery ...
Nonviral Platforms Streamline Gene Therapy Delivery
Complications of viral vectors can be avoided with DNA plasmids, engineered vesicles, cell-penetrating proteins, and other nonviral alternatives ...
Vesigen to Present at the 2023 Cell and Gene Meeting on the Mesa
CAMBRIDGE, Mass., October 5, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...
Vesigen Highlights New Data on Non-Viral Delivery Platform at the Exosome Based Therapeutic Development Summit
CAMBRIDGE, Mass., September 7, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...
Vesigen Highlights Therapeutic Platform for Non-Viral Delivery of Gene Editors and RNA at ASGCT 2023
Engineered ARMMs efficiently deliver CRISPR/Cas9 complexes, base editing complexes and RNA therapeutics Additional presentations demonstrate biodistribution to a range of ...
Stay Connected
